Top

Published in:

26-10-2023 | Steatotic Liver Disease

What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications

Authors: Mariana M. Ramírez-Mejía, Nahum Méndez-Sánchez

Published in: Current Hepatology Reports | Issue 4/2023

Abstract

Purpose of Review

This review aims to examine the evolution of terminology, diagnostic criteria, epidemiologic considerations, and clinical implications of the change from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction–associated fatty liver disease (MAFLD) and metabolic dysfunction–associated steatotic liver disease (MASLD).

Recent Findings

The classification and nomenclature NAFLD have been the subject of ongoing debate in the medical community. The development in recent years of MAFLD and MASLD is intended to address the limitations associated with NAFLD. Increasing evidence supporting the metabolic component of steatotic liver disease (SLD) has emerged in recent years, and key insights into the pathophysiologic mechanisms leading to the development of MAFLD/MASLD have been uncovered. Furthermore, a new classification of SLD, including MASLD and the overlapping of ALD and MASLD called MetALD, has been proposed as an international effort to unify the nomenclature.

Summary

This article sheds light on the rationale for the proposed change and its potential implications for research, patient management, and public health strategies.

Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283–98.PubMed

Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–700. https://doi.org/10.1210/clinem/dgac321.CrossRefPubMed

Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864–73. https://doi.org/10.1016/S2468-1253(21)00183-7.CrossRefPubMed

Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–51. https://doi.org/10.1038/s41575-022-00635-5.CrossRefPubMed

•• Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–9. https://doi.org/10.1016/j.jhep.2020.03.039. In this article, the renaming of NAFLD to MAFLD was proposed, providing an overview of the objectives and reasons that led to its proposal.

•• Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023. https://doi.org/10.1097/hep.0000000000000520. In this article, the term MASLD was proposed as well as a new classification of SLD, which takes into account the overlapping of ALD and MASLD.

Kawaguchi T, Tsutsumi T, Nakano D, Torimura T. MAFLD: renovation of clinical practice and disease awareness of fatty liver. Hepatol Res. 2022;52(5):422–32. https://doi.org/10.1111/hepr.13706.CrossRefPubMed

Gofton C, Upendran Y, Zheng MH, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepatol. 2023;29(Suppl):S17-s31. https://doi.org/10.3350/cmh.2022.0367.CrossRefPubMed

Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.PubMed

10.

Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology. 1994;107(4):1103–9. https://doi.org/10.1016/0016-5085(94)90235-6.CrossRefPubMed

11.

Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Dig Liver Dis. 2002;34(3):204–11. https://doi.org/10.1016/S1590-8658(02)80194-3.CrossRefPubMed

12.

Lonardo A, Bellini M, Tondelli E, Frazzoni M, Grisendi A, Pulvirenti M, et al. Nonalcoholic steatohepatitis and the “bright liver syndrome”: should a recently expanded clinical entity be further expanded? Am J Gastroenterol. 1995;90(11):2072–4.PubMed

13.

Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18(6):353–8. https://doi.org/10.1016/S0261-5614(99)80015-6.CrossRefPubMed

14.

Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–5. https://doi.org/10.1016/S0002-9343(99)00271-5.CrossRefPubMed

15.

Bellentani S, Tiribelli C. Is it time to change NAFLD and NASH nomenclature? Lancet Gastroenterol Hepatol. 2017;2(8):547–8. https://doi.org/10.1016/S2468-1253(17)30146-2.CrossRefPubMed

16.

Dixon JB, O’Brien PE, Bhathal PS. Reply. Gastroenterology. 2002;122(3):841–2. https://doi.org/10.1016/S0016-5085(02)80152-4.CrossRef

17.

Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202–19. https://doi.org/10.1002/hep.510380242.CrossRefPubMed

18.

Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23(1):72–82. https://doi.org/10.1159/000084728.CrossRefPubMed

19.

Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.CrossRefPubMed

20.

Attia D, Gomaa A, Abdel AS. Letter to the editor: pitfalls in the outcome differences between NAFLD and MAFLD. Hepatology. 2022;76(5):E100. https://doi.org/10.1002/hep.32563.CrossRefPubMed

21.

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–835. https://doi.org/10.1097/hep.0000000000000323.CrossRefPubMed

22.

Policarpo S, Carvalhana S, Craciun A, Crespo RR, Cortez-Pinto H. Do MAFLD Patients with harmful alcohol consumption have a different dietary intake? Nutrients. 2022;14(7):1335. https://doi.org/10.3390/nu14071335.CrossRefPubMedPubMedCentral

23.

Sun FR, Wang BY. Alcohol and metabolic-associated fatty liver disease. J Clin Transl Hepatol. 2021;9(5):719–30. https://doi.org/10.14218/jcth.2021.00173.CrossRefPubMedPubMedCentral

24.

Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172-81.e6. https://doi.org/10.1016/j.cgh.2021.05.029.CrossRefPubMed

25.

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–47. https://doi.org/10.1097/hep.0000000000000004.CrossRefPubMed

26.

Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, et al. Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Hepatology. 2023;77(4):1404–27. https://doi.org/10.1002/hep.32774.CrossRefPubMed

27.

Henry L, Paik J, Younossi ZM. Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world. Aliment Pharmacol Ther. 2022;56(6):942–56. https://doi.org/10.1111/apt.17158.CrossRefPubMed

28.

Castellanos-Fernandez MI, Pal SC, Arrese M, Arab JP, George J, Méndez-Sánchez N. Nonalcoholic fatty liver disease in Latin America and Australia. Clin Liver Dis. 2023;27(2):301–15. https://doi.org/10.1016/j.cld.2023.01.015.CrossRefPubMed

29.

Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619-29.e7. https://doi.org/10.1016/j.cgh.2021.11.038.CrossRefPubMed

30.

Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161-71.e5. https://doi.org/10.1016/j.cgh.2020.10.046.CrossRefPubMed

31.

Wang Y, Yu Y, Zhang H, Chen C, Wan H, Chen Y, et al. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Front Endocrinol (Lausanne). 2022;13:968766. https://doi.org/10.3389/fendo.2022.968766.CrossRefPubMed

32.

Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, et al. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab. 2023;14:20420188221145548. https://doi.org/10.1177/20420188221145549.CrossRefPubMedPubMedCentral

33.

Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol. 2022;10(2):329–38. https://doi.org/10.14218/jcth.2021.00178.CrossRefPubMed

34.

Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85. https://doi.org/10.1161/atv.0000000000000153.CrossRefPubMed

35.

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. https://doi.org/10.1016/j.jhep.2019.06.021.CrossRefPubMed

36.

Lazarus JV, Mark HE, Villota-Rivas M, Palayew A, Carrieri P, Colombo M, et al. The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge? J Hepatol. 2022;76(4):771–80. https://doi.org/10.1016/j.jhep.2021.10.025.CrossRefPubMed

37.

Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65(8):1038–48. https://doi.org/10.1016/j.metabol.2015.12.012.CrossRefPubMed

38.

Baratta F, Ferro D, Pastori D, Colantoni A, Cocomello N, Coronati M, et al. Open issues in the transition from NAFLD to MAFLD: the experience of the Plinio study. Int J Environ Res Public Health. 2021;18(17):8993. https://doi.org/10.3390/ijerph18178993.CrossRefPubMedPubMedCentral

39.

Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. https://doi.org/10.3390/ijms222111629.CrossRefPubMedPubMedCentral

40.

Kořínková L, Pražienková V, Černá L, Karnošová A, Železná B, Kuneš J, et al. Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides. Front Endocrinol (Lausanne). 2020;11:597583. https://doi.org/10.3389/fendo.2020.597583.CrossRefPubMed

41.

Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). J Diabetes Res. 2020;2020:3920196. https://doi.org/10.1155/2020/3920196.CrossRefPubMedPubMedCentral

42.

Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021;2021:6613827. https://doi.org/10.1155/2021/6613827.CrossRefPubMedPubMedCentral

43.

Pal SC, Eslam M, Mendez-Sanchez N. Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones (Athens). 2022;21(4):573–89. https://doi.org/10.1007/s42000-022-00391-w.CrossRefPubMed

44.

Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of insulin resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. https://doi.org/10.3390/ijms22084156.CrossRefPubMedPubMedCentral

45.

Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol. 2018;68(2):280–95. https://doi.org/10.1016/j.jhep.2017.11.014.CrossRefPubMed

46.

Mota M, Banini BA, Cazanave SC, Sanyal AJ. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1049–61. https://doi.org/10.1016/j.metabol.2016.02.014.CrossRefPubMedPubMedCentral

47.

Mendez-Sanchez N, Cruz-Ramon VC, Ramirez-Perez OL, Hwang JP, Barranco-Fragoso B, Cordova-Gallardo J. New aspects of lipotoxicity in nonalcoholic steatohepatitis. Int J Mol Sci. 2018;19(7):2034. https://doi.org/10.3390/ijms19072034.CrossRefPubMedPubMedCentral

48.

Mantovani A. MAFLD vs NAFLD: where are we? Dig Liver Dis. 2021;53(10):1368–72. https://doi.org/10.1016/j.dld.2021.05.014.CrossRefPubMed

49.

Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, et al. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int. 2021;41(2):255–60. https://doi.org/10.1111/liv.14739.CrossRefPubMed

50.•

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–90. https://doi.org/10.1016/s2468-1253(22)00062-0. This article endorses the term MAFLD and its definition for fatty liver diseases associated with metabolic dysregulation by more than 1000 stakeholders.

51.

Sarin SK, Eslam M, Fan JG, Lin HC, George J, Omata M. MAFLD, patient-centred care, and APASL. Hepatol Int. 2022;16(5):1032–4. https://doi.org/10.1007/s12072-022-10408-6.CrossRefPubMed

52.

Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int. 2020;40(12):3018–30. https://doi.org/10.1111/liv.14675.CrossRefPubMed

53.

Saffo S, Do A. Clinical phenotyping and the application of precision medicine in MAFLD. Clin Liver Dis (Hoboken). 2022;19(6):227–33. https://doi.org/10.1002/cld.1199.CrossRefPubMed

54.

Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74(4):989–91. https://doi.org/10.1016/j.jhep.2020.12.016.CrossRefPubMed

55.

Méndez-Sánchez N, Pal SC, Fassio E, Díaz-Ferrer J, Prado-Robles JA. MAFLD: perceived stigma-a single-center Mexican patient survey. Hepatol Int. 2023;17(2):507–8. https://doi.org/10.1007/s12072-022-10448-y.CrossRefPubMed

56.

Portincasa P. NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care. Intern Emerg Med. 2023. https://doi.org/10.1007/s11739-023-03203-0.CrossRefPubMedPubMedCentral

57.

Shiha G, Korenjak M, Casanovas T, Mooney V, Sigurðardóttir S, Koulla Y, et al. MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. J Hepatol. 2022;77(6):1717–9. https://doi.org/10.1016/j.jhep.2022.08.027.CrossRefPubMed

58.

Younossi ZM, Rinella ME, Sanyal AJ, Harrison SA, Brunt EM, Goodman Z, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–8. https://doi.org/10.1002/hep.31420.CrossRefPubMed

59.

Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150–63. https://doi.org/10.3350/cmh.2021.0310.CrossRefPubMed

60.

Díaz LA, Fuentes-López E, Ayares G, Idalsoaga F, Arnold J, Márquez-Lomas A, et al. The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas. Lancet Gastroenterol Hepatol. 2022;7(6):552–9. https://doi.org/10.1016/s2468-1253(22)00008-5.CrossRefPubMed

Title: What Is in a Name: from NAFLD to MAFLD and MASLD—Unraveling the Complexities and Implications
Authors: Mariana M. Ramírez-Mejía
Nahum Méndez-Sánchez
Publication date: 26-10-2023
Publisher: Springer US
Keywords: Steatotic Liver Disease
Obesity
Obesity
Metabolic Dysfunction-Associated Steatotic Liver Disease
Published in: Current Hepatology Reports / Issue 4/2023
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-023-00620-9

Interventional Radiology and Surgical Treatment Options for Non-Cirrhotic Portal Hypertension

Portal Vein Thrombosis

Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy

Open Access
Gene Therapy in Oncology

Risk of Liver Cancer in MASLD: Role of Genetic Risk Scores

Hepatocellular Carcinoma

Obliterative Portal Venopathy

Portal Vein Thrombosis

Current Situation of Palliative Care Services Within Hepatology

Care

Portal Vein Thrombosis in Adults without Cirrhosis

Portal Vein Thrombosis

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Keynote webinar | Spotlight on adolescent vaping

Live
Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET

Prof. Ann McNeill

Dr. Debbie Robson

Benji Horwell

Developed by: Springer Medicine

Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty in Geriatric Patients
On-demand webinar

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft

Prof. Barbara C. van Munster

Prof. Mirko Petrovic

Developed by: Springer Medicine

Watch now

A quick guide to ECGs

Electrocardiography
Training Course

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date.

PD Dr. Carsten W. Israel

Developed by: Springer Medizin

Start the cases

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content